Amylyx Pharmaceuticals, Inc.

NasdaqGS:AMLX Voorraadrapport

Marktkapitalisatie: US$200.2m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Amylyx Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

De omzet van Amylyx Pharmaceuticals zal naar verwachting dalen met 78.7% per jaar, terwijl de jaarlijkse winst naar verwachting zal groeien met 27.7% per jaar. De winst per aandeel zal naar verwachting groeien met 34% per jaar.

Belangrijke informatie

27.7%

Groei van de winst

34.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei23.8%
Inkomstengroei-78.7%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt13 Aug 2024

Recente toekomstige groei-updates

Recent updates

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Jun 25

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Apr 25
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Mar 12
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

An ALS Drug Fails Again

Mar 09

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Feb 23

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Feb 23
Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Nov 10
Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Sep 24
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

May 16
This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Apr 20
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Mar 16
Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Dec 19
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Oct 07

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Sep 30

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Sep 08

Amylyx plunges 28% after FDA briefing documents on ALS drug

Sep 02

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Aug 29
We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01

Aug 11

Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada

Jul 29

Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates

Jul 18

Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis

Jul 04

Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last

Jun 17

Winst- en omzetgroeiprognoses

NasdaqGS:AMLX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20260-83N/AN/A5
12/31/2025N/A-109N/AN/A6
12/31/202488-233N/AN/A6
6/30/2024299-166-60-59N/A
3/31/2024398-711517N/A
12/31/2023381491112N/A
9/30/20232942-53-51N/A
6/30/2023192-73-91-89N/A
3/31/202394-149-147-144N/A
12/31/202222-198-182-180N/A
9/30/20220-184-161-158N/A
6/30/20220-153-138-136N/A
3/31/20220-121-103-103N/A
12/31/20210-88-75-75N/A
9/30/20211-68-56-55N/A
12/31/20201-42-37-37N/A
12/31/20191-14-11-11N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat AMLX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat AMLX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat AMLX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van AMLX zal naar verwachting de komende 3 jaar dalen ( -78.7% per jaar).

Hoge groei-inkomsten: De omzet van AMLX zal naar verwachting de komende 3 jaar dalen ( -78.7% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van AMLX naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y